Use access key #2 to skip to page content.

Four star stock poised to pop, Lexicon Pharmaceuticals

Recs

4

November 24, 2009 – Comments (10) | RELATED TICKERS: LXRX

      With many key trial results being announced over the next 12 months,this biotech seems like a logical addition to anyones portfolio,with a fairly low degree of risk at this currently depressed stock price of $1.63         Key Developments   (LXRX) Lexicon completed patient enrollment ahead of schedule in a Phase 2a clinical trial of its drug candidate for non-constipating irritable bowel syndrome (IBS), LX1031, an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract.  Top-line data from the trial is expected to be available in November 2009, with detailed results available in the first quarter of 2010.Lexicon completed Phase 1 studies of its drug candidate for type 2 diabetes, LX4211, an inhibitor of sodium-glucose cotransporter 2 (SGLT2).  The company also initiated a Phase 2a clinical trial of the drug candidate in patients with diabetes.  In the Phase 1 clinical trial, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion.  LX4211 also demonstrated a favorable pharmacokinetic profile supporting the potential for once daily dosing.  The Phase 2 clinical trial is designed as a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX4211 and its effect on biomarkers associated with type 2 diabetes.  The trial will be conducted in the United States and is expected to enroll 36 patients with non-insulin dependent type 2 diabetes.  Top-line data from the trial is expected to be available in the first quarter of 2010.Lexicon advanced LX2931, an inhibitor of sphingosine-1-phosphate (S1P) lyase, into a Phase 2a study in patients with rheumatoid arthritis.  The Phase 2 clinical trial is designed as a 12-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX2931 and its effects on symptoms associated with rheumatoid arthritis.  The study will include up to 120 patients and will be conducted at multiple centers in the United States and Eastern Europe.  Top-line data from the trial is expected to be available in the third quarter of 2010. Lexicon continues to enroll patients in a Phase 2a study of its drug candidate for carcinoid syndrome, LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.  The Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome.  The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy.  Top-line data from the trial is expected to be available by the third quarter of 2010.In October 2009, Lexicon completed the public offering and sale of 38.3 million shares of its common stock at $1.50 per share.  The net proceeds of the offering were $55.2 million, after deducting underwriting discounts and offering expenses.  http://www.lexicon-genetics.com/pipeline/index.html      Full disclosure,  Long LXRX  (14,000 shares) and adding more under $2.00  This Is not a ( FOOLISH)  Investment for longer term Investors.   TS

10 Comments – Post Your Own

#1) On November 24, 2009 at 9:48 PM, anchak (99.85) wrote:

This is a Hans ( Porte) pick - and I think the technicals are decent -the day to buy was at 1.31 when it was at Long term support

Report this comment
#2) On November 24, 2009 at 10:15 PM, topsecret09 (40.28) wrote:

#1) On November 24, 2009 at 9:48 PM, anchak (99.74) wrote: This is a Hans ( Porte) pick - and I think the technicals are decent -the day to buy was at 1.31 when it was at Long term support    Yea ,Port likes this one too.  I bought In $1.30 range also. I will be readjusting my real portfolio soon. I will sell a couple of the other names that I have, and buy more of this. While I believe that diversification has Its merits,In some cases (like this one) I think It Is better to find the right horse and ride It....... TS  

Report this comment
#3) On November 25, 2009 at 3:38 PM, topsecret09 (40.28) wrote:

  Back to $1.51 @  12:37 pacific time on Wednesday Nov,25th....       buying more........  TS

Report this comment
#4) On November 27, 2009 at 9:50 AM, topsecret09 (40.28) wrote:

  Trading at  1.43 ...  Black Friday sale !!!  BUY    BUY    BUY   !!!!!!!!!!   TS

Report this comment
#5) On November 27, 2009 at 11:49 PM, topsecret09 (40.28) wrote:

   Diabetes treatment costs to triple by 2034.......   http://www.cnn.com/2009/HEALTH/11/26/diabetes.projections/

Report this comment
#6) On November 28, 2009 at 2:30 AM, tkell31 (< 20) wrote:

Just a suggestion, but it doesnt seem like this should be going anywhere before July or August next year so why not park your money in a safer stock and sell some covered calls?  Since you are following this stock you should know when it was going to go up in value prior the 99% of the investing community.  For example SQNM is selling for 4.15 or so and the dec 5 call is selling for roughly an 8% premium.  If you have 20K shares of this you could buy approximately 6700 shres of sqnm, sell 67 call options generating $1675 in immediate income (less fees), with the potential to make up to another $5000 or so if the shares were to get called away.  Do that for five or six months and you will make a nice amount of money barring SQNM going bankrupt and be able to buy even more shares of lxrx.

Report this comment
#7) On November 30, 2009 at 1:33 PM, topsecret09 (40.28) wrote:

   Buy   Buy   Buy      $1.44 .........       TS

Report this comment
#8) On December 06, 2009 at 12:14 PM, topsecret09 (40.28) wrote:

 Stock closed @ $1.68  On Friday December 4th....   Latest presentation {Gastro 2009}.....     http://www.lexicon-genetics.com/LX1031_GASTRO_2009.html    TS

Report this comment
#9) On December 12, 2009 at 5:29 PM, topsecret09 (40.28) wrote:

 Stock closed @ $1.80 on Friday December 11th....   Chart/technicals getting better.......   TS

Report this comment
#10) On December 15, 2009 at 12:11 PM, topsecret09 (40.28) wrote:

  Intra-day stock @ $1.93  Tuesday December 15th  TS

Report this comment

Featured Broker Partners


Advertisement